Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) – HC Wainwright decreased their Q2 2026 earnings per share estimates for Kyverna Therapeutics in a report released on Friday, May 15th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.69) for the quarter, down from their previous estimate of ($0.65). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($2.98) EPS, Q1 2027 earnings at ($0.85) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.79) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($3.01) EPS.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09.
View Our Latest Report on KYTX
Kyverna Therapeutics Price Performance
Kyverna Therapeutics stock opened at $8.54 on Tuesday. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $519.15 million, a PE ratio of -2.60 and a beta of 2.05. Kyverna Therapeutics has a 12 month low of $2.06 and a 12 month high of $13.67. The stock has a 50-day moving average price of $9.05 and a two-hundred day moving average price of $8.39.
Institutional Investors Weigh In On Kyverna Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Kyverna Therapeutics by 31.1% in the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after purchasing an additional 16,267 shares in the last quarter. AQR Capital Management LLC bought a new stake in Kyverna Therapeutics in the first quarter worth approximately $137,000. Rhumbline Advisers increased its holdings in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Kyverna Therapeutics in the second quarter worth approximately $107,000. Institutional investors and hedge funds own 18.08% of the company’s stock.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Read More
- Five stocks we like better than Kyverna Therapeutics
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
